Table 3.
Treatment characteristics in colistin and ceftolozane/tazobactam treated patient groups.
| Variable | CMS group (n = 33) | C/T group (n = 18) | p value |
|---|---|---|---|
| Length of ICU stay (days) | 26 (17; 33) | 25 (19; 47) | 0.49a |
| Duration of mechanical ventilation (days) | 24 (13; 31) | 20 (14; 38) | 0.79a |
| Medical patient | 26 (78.8%) | 15 (83.3%) | 1.00b |
| Surgical patient | 7 (21.2%) | 3 (16.7%) | 1.00b |
| Tracheostomy | 19 (57.6%) | 9 (50.0%) | 0.60b |
| IRRT | 7 (21.2%) | 5 (27.8%) | 0.73b |
| CRRT | 7 (21.2%) | 5 (27.8%) | 0.73b |
| Polymicrobial infection | 8 (24.2%) | 3 (16.6%) | 0.40b |
| P. aeruginosa bacteremia | 3 (9.0%) | 1 (5.5%) | 1.00b |
| Days of antibiotic therapy | 9 (6; 11) | 7 (6; 8) | 0.18a |
| Combination therapy | 32 (97%) | 8 (44.4%) | 0.001b* |
Data are expressed as median (interquartile range) and absolute numbers (percentage).
CRRT continuous renal replacement therapy, CMS colistimethate sodium, C/T ceftolozane/tazobactam, ICU intensive care unit, IRRT intermittent renal replacement therapy, P. aeruginosa Pseudomonas aeruginosa.
aMann–Whitney U test.
bχ2 test or Fisher’s exact test.
*p < 0.05.